Enrolling in an Invasive Ductal Carcinoma Clinical Trial

CLINICAL TRIAL 16933
Older Breast Cancer Patients: Risk For Cognitive Decline
Condition: Breast
Intervention:

CLINICAL TRIAL 19000
Evaluation of Anti-Her2 and Anti-Her3 T-Helper Response in Primary Breast Cancer
Condition: Breast
Intervention: Not Applicable ()

CLINICAL TRIAL 19209
Combined Imaging and Blood Biomarkers for Breast Cancer Diagnosis
Condition: Healthy Subjects
Intervention:

CLINICAL TRIAL 19646
Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Condition: Breast
Intervention: Carvedilol (); Not Applicable ()

CLINICAL TRIAL 20030
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Positive Breast Cancer
Condition: Breast
Intervention: Not Applicable ()

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 20897
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
Condition: Breast
Intervention: Adriamycin (doxorubicin); DC1 Vaccine (); Neulasta (pegfilgrastim); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Taxol (paclitaxel); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); paclitaxel (); pegfilgrastim ()

CLINICAL TRIAL 20915
Neoadjuvant Therapy of HER2 directed Dendritic Cell (DC1) vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer (NATASHA trial)
Condition: Breast
Intervention: DC1 Vaccine (); Herceptin (Trastuzumab); Pertuzumab (); Taxol (paclitaxel); Trastuzumab (); paclitaxel (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 21093
Phase 1/1b/2 Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients with Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer
Condition: Breast
Intervention: Faslodex (fulvestrant); PMD-026 (); fulvestrant ()

CLINICAL TRIAL 21378
Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer
Condition: Breast
Intervention: CD4+ T Cells (); DC1 Vaccine (); Herceptin (Trastuzumab); Pepinemab (VX15/2503); Trastuzumab (); cyclophosphamide (); cytoxan (cyclophosphamide); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:

CLINICAL TRIAL 21673
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety ofHER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-Based Therapy (FLAMINGO-01)
Condition: Breast
Intervention: GLSI-100 (); Placebo ()

CLINICAL TRIAL 21676
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases (TARGET-TNBC)
Condition: Breast
Intervention: Sacituzumab Govitecan (); Zimberelimab ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 21899
Phase Ib Expansion Study of CX-5461 in Patients with Solid Tumours and BRCA2 and/or PALB2 Mutation
Condition: Multiple
Intervention: CX-5461 ()

CLINICAL TRIAL 22102
A Phase 1b, First-in-human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors
Condition: Multiple
Intervention: XMT-1660 ()

CLINICAL TRIAL 17268-B
I-SPY 2.2 TRIAL - Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
Condition: Breast
Intervention: AKTi (); AMP-514 (Durvalumab); ARV-471 (); ARX-788 (); Abemaciclib (); Adriamycin (doxorubicin); Cemiplimab (); DAN-222 (); Datopotamab Deruxtecan (); Dostarlimab (); Durvalumab (); Femara (Letrozole); GSK5733584 (); Herceptin (Trastuzumab); LY2835219 (Abemaciclib); Lasofoxifene (); Letrozole (); MEDI4736 (Durvalumab); Niraparib (); PD-1 (); PD-L1 (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pertuzumab (); REGN2810 (Cemiplimab); Rilvegostomig (); Sarilumab (); T-Dxd (); TSR-042 (Dostarlimab); Taxol (paclitaxel); Taxotere (docetaxel); Trastuzumab (); VV1 (); Z-endoxifen (); Zanidatamab (); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); docetaxel (); doxorubicin (); paclitaxel (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 22305
First-in-Human Study of STX-478, a Mutant-Selective PI3Ka Inhibitor as Monotherapy and in Combination with Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: 772256 (Palbociclib); Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Ribociclib (); STX478-101 (); fulvestrant ()

CLINICAL TRIAL 22356
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimistation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
Condition: Breast
Intervention: 772256 (Palbociclib); Abemaciclib (); Aromasin (Exemestane); EP0062 (); Elacestrant (); Exemestane (); Faslodex (fulvestrant); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Palbociclib (); Ribociclib (); everolimus (RAD001); fulvestrant ()

CLINICAL TRIAL 22515
Genomic Alterations of PI3K Pathway in HER2-Positive Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 22617
A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer
Condition: Breast
Intervention: Abemaciclib (); DS-8201a (Trastuzumab Deruxtecan); Faslodex (fulvestrant); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Ribociclib (); Sacituzumab Govitecan (); Taxotere (docetaxel); Trastuzumab Deruxtecan (); Xeloda (capecitabine); capecitabine (); cyclophosphamide (); cytoxan (cyclophosphamide); docetaxel (); fulvestrant ()

CLINICAL TRIAL 22706
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Condition: Breast
Intervention: Disitamab Vedotin (); Tucatinib ()

CLINICAL TRIAL 23142
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Condition: Breast
Intervention: DC1 Vaccine ()

CLINICAL TRIAL 23161
Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
Condition: Breast
Intervention: DC1 Vaccine (); Elacestrant ()

CLINICAL TRIAL 23179
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients Throughout Florida
Condition: Multiple
Intervention:

CLINICAL TRIAL 23249
PRE-I-SPY TRIAL - PRE-Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis: A Phase I/Ib platform trial
Condition: Breast
Intervention: ALX148 (); Cemiplimab (); REGN2810 (Cemiplimab); T-Dxd (); Tucatinib (); Vidutolimod (); Zanidatamab ()

CLINICAL TRIAL 23250
Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer
Condition: Breast
Intervention: AMP-514 (Durvalumab); CP-675,206 (tremelimumab); Durvalumab (); Gemzar (gemcitabine); MEDI4736 (Durvalumab); Nab-paclitaxel (Abraxane); Neoantigen (); Paraplatin (carboplatin); Sacituzumab Govitecan (); carboplatin (); gemcitabine (); tremelimumab ()

CLINICAL TRIAL 23255
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Olaparib (Lynparza); XL309 ()

CLINICAL TRIAL 23340
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Condition: Breast
Intervention: Alisertib (MLN8237); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 23366
Patient-Reported Outcomes in Recipients of Intralesional Vaccines for Breast Cancer at Moffitt Cancer Center
Condition: Breast
Intervention:

CLINICAL TRIAL 23367
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer
Condition: Breast
Intervention: RGT419B ()

CLINICAL TRIAL 23378
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of AVZO-021 as a single agent and in combination therapy in patients with advanced solid tumors
Condition: Breast
Intervention: 772256 (Palbociclib); AVZO-021 (); Abemaciclib (); Faslodex (fulvestrant); Femara (Letrozole); LEE011 (Ribociclib); LY2835219 (Abemaciclib); Letrozole (); Palbociclib (); Paraplatin (carboplatin); Ribociclib (); Sacituzumab Govitecan (); carboplatin (); fulvestrant ()

CLINICAL TRIAL 23393
A Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer
Condition: Breast
Intervention: PCS6422 (); Xeloda (capecitabine); capecitabine ()

CLINICAL TRIAL 23426
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Study)
Condition: Breast
Intervention: Not Applicable ()

CLINICAL TRIAL 23433
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer following Neoadjuvant Chemotherapy and Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()

CLINICAL TRIAL 23521
High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy
Condition: Breast
Intervention:

CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()

CLINICAL TRIAL 23585
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
Condition: Breast
Intervention: Avastin (Bevacizumab); BBO-10203 (); Bevacizumab (); FOLFOX (); Faslodex (fulvestrant); Herceptin (Trastuzumab); LEE011 (Ribociclib); Ribociclib (); Trastuzumab (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 23513
Assessing the DCIS Test Effect on Treatment Strategies in Patients with Ductal Carcinoma in Situ After Breast-Conserving Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23572
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

CLINICAL TRIAL 23553
DENALI-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod CAR T, in Heterozygous HLA A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA A*02 Expression.
Condition: Immunotherapy
Intervention: A2B395 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23559
Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors
Condition: Breast
Intervention:

CLINICAL TRIAL 23571
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
Condition: Breast
Intervention:

CLINICAL TRIAL 23678
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen (); Testosterone + Anastrozole (); Z-endoxifen ()

CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()

CLINICAL TRIAL 23719
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Condition: Breast
Intervention: 772256 (Palbociclib); Femara (Letrozole); Inavolisib/Placebo (); Letrozole (); Palbociclib ()

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()